{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:38:56Z","timestamp":1760852336200,"version":"3.33.0"},"reference-count":33,"publisher":"Japanese Society for the Study of Xenobiotics","issue":"5","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2007]]},"DOI":"10.2133\/dmpk.22.336","type":"journal-article","created":{"date-parts":[[2007,10,25]],"date-time":"2007-10-25T04:17:01Z","timestamp":1193285821000},"page":"336-349","source":"Crossref","is-referenced-by-count":12,"title":["In Vitro Metabolism of CP-122,721 ((2S,3S)-2-Phenyl-3-[(5-Trifluoromethoxy-2-Methoxy)Benzylamino]Piperidine), a Non-Peptide Antagonist of the Substance P Receptor"],"prefix":"10.2133","volume":"22","author":[{"given":"R.","family":"Scott Obach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannine M.","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Logman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"900","reference":[{"key":"10.2133\/dmpk.22.336_bb0005","first-page":"900","article-title":"Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor","volume":"277","author":"McLean","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.2133\/dmpk.22.336_bb0010","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0960-894X(98)00012-2","article-title":"Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist","volume":"8","author":"Rosen","year":"1998","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.2133\/dmpk.22.336_bb0015","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/jnci\/89.11.817","article-title":"Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin","volume":"89","author":"Kris","year":"1997","journal-title":"J. Nat. Cancer Inst."},{"key":"10.2133\/dmpk.22.336_bb0020","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1126\/science.281.5383.1640","article-title":"Distinct mechanism for antidepressant activity by blockade of central substance P receptors","volume":"281","author":"Kramer","year":"1998","journal-title":"Science"},{"key":"10.2133\/dmpk.22.336_bb0025","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1200\/JCO.1999.17.1.338","article-title":"Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis","volume":"17","author":"Hesketh","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.2133\/dmpk.22.336_bb0030","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1097\/00000542-200010000-00009","article-title":"Substance P (neurokinin-1) antagonist prevents postoperative vomiting after abdominal hysterectomy procedures","volume":"93","author":"Gesztesi","year":"2000","journal-title":"Anesthesiology"},{"key":"10.2133\/dmpk.22.336_bb0035","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1016\/S0021-9258(20)82244-3","article-title":"The carbon monoxide binding pigment of liver microsomes","volume":"239","author":"Omura","year":"1964","journal-title":"J. Biol. Chem."},{"key":"10.2133\/dmpk.22.336_bb0040","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/BF01059688","article-title":"Hepatic clearance of drugs. I. Theoretical considerations of a \u201cwell-stirred\u201d model and a \u201cparallel tube\u201d model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance","volume":"5","author":"Pang","year":"1977","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.2133\/dmpk.22.336_bb0045","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","article-title":"The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective","volume":"31","author":"Bjornsson","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.22.336_bb0050","series-title":"Metabolic Drug Interactions","first-page":"603","article-title":"Antiarrythmics","author":"Brosen","year":"2000"},{"key":"10.2133\/dmpk.22.336_bb0055","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1023\/A:1018906614320","article-title":"Inhibition of CYP3A catalyzed 1\u2032-hydroxymidazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine","volume":"11","author":"Wrighton","year":"1994","journal-title":"Pharm. Res."},{"key":"10.2133\/dmpk.22.336_bb0060","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0090-9556(24)15274-9","article-title":"Inhibition of CYP3A in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression","volume":"27","author":"Gibbs","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.22.336_bb0065","first-page":"3317","article-title":"Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients","volume":"59","author":"Mollerup","year":"1999","journal-title":"Cancer Res."},{"key":"10.2133\/dmpk.22.336_bb0070","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0090-9556(24)14911-2","article-title":"Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole","volume":"27","author":"Paine","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.22.336_bb0075","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1039\/c39820000055","article-title":"Magnitude of the kinetic isotope effect for the oxidative demethylation of anisole and [Me-2H3]anisole; a new and simple criterion for assessing model systems for cytochrome P450 dependent mono-oxygenases","author":"Lindsay-Smith","year":"1982","journal-title":"J. Chem. Soc. Chem. Comm."},{"key":"10.2133\/dmpk.22.336_bb0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/00498258409151396","article-title":"Rate-limiting steps in cytochrome P-450 catalyzed reactions; studies on isotope effects in the O-deethylation of 7-ethoxycoumarin","volume":"14","author":"Lu","year":"1984","journal-title":"Xenobiotica"},{"key":"10.2133\/dmpk.22.336_bb0085","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0003-9861(85)90822-7","article-title":"Kinetic isotope effects on cytochrome P-450 catalyzed oxidation reactions: full expression of the intrinsic isotope effect during the O-deethylation of 7-ethoxycoumarin by liver microsomes from 3-methylcholanthrene-induced hamsters","volume":"239","author":"Miwa","year":"1985","journal-title":"Arch. Biochem. Biophys."},{"key":"10.2133\/dmpk.22.336_bb0090","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/abbi.1994.1185","article-title":"Novel metabolic pathway of arylethers by cytochrome P450: cleavage of the oxygen-aromatic ring bond accompanying ipso-substitution by the oxygen atom of the active species in cytochrome P450 models and cytochrome P450","volume":"310","author":"Ohe","year":"1994","journal-title":"Arch. Biochem. Biophys."},{"key":"10.2133\/dmpk.22.336_bb0095","doi-asserted-by":"crossref","first-page":"7681","DOI":"10.1016\/0040-4039(95)01611-K","article-title":"Novel oxidative pathway of para-substituted phenols in cytochrome P450 chemical model: substituent elimination accompanying ipso-substitution by the oxygen atom of the active species","volume":"36","author":"Ohe","year":"1995","journal-title":"Tet. Lett."},{"key":"10.2133\/dmpk.22.336_bb0100","first-page":"116","article-title":"Substituent elimination from p-substituted phenols by cytochrome P450. ipso-Substitution by the oxygen atom of the active species","volume":"25","author":"Ohe","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.22.336_bb0105","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/abbi.2001.2665","article-title":"Ipso-substitution by cytochrome P450 with conversion of p-hydroxybenzene derivatives to hydroquinone: evidence for hydroperoxoiron as the active oxygen species","volume":"397","author":"Vatsis","year":"2002","journal-title":"Arch. Biochem. Biophys."},{"key":"10.2133\/dmpk.22.336_bb0110","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-3565(24)36999-X","article-title":"The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data","volume":"283","author":"Obach","year":"1997","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.2133\/dmpk.22.336_bb0115","first-page":"1359","article-title":"Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol","volume":"25","author":"Obach","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.22.336_bb0120","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0090-9556(24)14938-0","article-title":"Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes","volume":"27","author":"Obach","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.22.336_bb0125","first-page":"1332","article-title":"Influence of microsomal concentration on apparent intrinsic clearance: implications for scaling in vitro data","volume":"29","author":"Kalvass","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.22.336_bb0130","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0022-3565(24)39241-9","article-title":"Microsomal binding of amitripty-line: effect on estimation of enzyme kinetic parameters in vitro","volume":"293","author":"Venkatakrishnan","year":"2000","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.2133\/dmpk.22.336_bb0135","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.CIR.75.4.785","article-title":"Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences","volume":"75","author":"Siddoway","year":"1987","journal-title":"Circulation"},{"issue":"Suppl 2","key":"10.2133\/dmpk.22.336_bb0140","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/0269881195009002011","article-title":"The SSRIs: advantages, disadvantages, and differences","volume":"9","author":"Lane","year":"1995","journal-title":"J. Psychopharm."},{"key":"10.2133\/dmpk.22.336_bb0145","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/jps.2600781003","article-title":"Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study","volume":"78","author":"Chakraborty","year":"1989","journal-title":"J. Pharm. Sci."},{"key":"10.2133\/dmpk.22.336_bb0150","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1124\/dmd.106.014266","volume":"35","author":"Colizza","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.22.336_bb0155","series-title":"Enzyme Systems That Metabolise Drugs and Other Xenobiotics","article-title":"Amine oxidases and the metabolism of xenobiotics","author":"Tipton","year":"2002"},{"key":"10.2133\/dmpk.22.336_bb0160","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3109\/00498259509061886","article-title":"Radical cation intermediates in N-dealkylation reactions","volume":"25","author":"Guengerich","year":"1995","journal-title":"Xenobiotica"},{"key":"10.2133\/dmpk.22.336_bb0165","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/00498250600594444","article-title":"Metabolism, pharmacokinetics and excretion of a potent tachykinin NK1 receptor antagonist (CP-122,721) in rat: Characterization of a novel oxidative pathway","volume":"36","author":"Kamel","year":"2006","journal-title":"Xenobiotica"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715302706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715302706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T21:44:30Z","timestamp":1737495870000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436715302706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007]]}},"alternative-id":["S1347436715302706"],"URL":"https:\/\/doi.org\/10.2133\/dmpk.22.336","relation":{},"ISSN":["1347-4367"],"issn-type":[{"type":"print","value":"1347-4367"}],"subject":[],"published":{"date-parts":[[2007]]}}}